467 related articles for article (PubMed ID: 18799188)
1. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.
Wang X; MacLennan GT; Zhang S; Montironi R; Lopez-Beltran A; Tan PH; Foster S; Baldridge LA; Cheng L
Hum Pathol; 2009 Feb; 40(2):211-7. PubMed ID: 18799188
[TBL] [Abstract][Full Text] [Related]
2. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
3. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
5. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
6. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
[TBL] [Abstract][Full Text] [Related]
7. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
8. Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin.
Sung MT; Zhang S; MacLennan GT; Lopez-Beltran A; Montironi R; Wang M; Tan PH; Cheng L
Clin Cancer Res; 2008 Apr; 14(7):1947-55. PubMed ID: 18381932
[TBL] [Abstract][Full Text] [Related]
9. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
11. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.
Jones TD; Zhang S; Lopez-Beltran A; Eble JN; Sung MT; MacLennan GT; Montironi R; Tan PH; Zheng S; Baldridge LA; Cheng L
Am J Surg Pathol; 2007 Dec; 31(12):1861-7. PubMed ID: 18043040
[TBL] [Abstract][Full Text] [Related]
12. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
13. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.
Wang X; Zhang S; MacLennan GT; Eble JN; Lopez-Beltran A; Yang XJ; Pan CX; Zhou H; Montironi R; Cheng L
Clin Cancer Res; 2007 Feb; 13(3):953-7. PubMed ID: 17289890
[TBL] [Abstract][Full Text] [Related]
15. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
16. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
[TBL] [Abstract][Full Text] [Related]
17. Primary heterologous carcinosarcoma (metaplastic carcinoma) of the urinary bladder: a clinicopathologic, immunohistochemical, and ultrastructural analysis of eight cases and a review of the literature.
Perret L; Chaubert P; Hessler D; Guillou L
Cancer; 1998 Apr; 82(8):1535-49. PubMed ID: 9554532
[TBL] [Abstract][Full Text] [Related]
18. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]